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ABSTRACT
Introduction Vasa previa is a condition where fetal blood 
vessels run unprotected in the membranes, outside the 
umbilical cord, and cross the internal opening of the cervix. 
During rupture of membranes, these vessels can rupture 
and put the baby at serious risk of severe blood loss and 
death. Numerous studies are being conducted to improve 
diagnostic modalities and establish clear management 
plans to improve pregnancy outcomes. However, the lack 
of a standardised set of outcomes for studies on vasa 
previa makes it difficult to compare study findings and 
draw meaningful conclusions. Through this project, we will 
be developing a core outcome set for studies on pregnant 
women with vasa previa (COVasP).
Methods and analysis The development of COVasP will 
involve five steps. The first will be a systematic review, 
in which we will generate a long list of outcomes based 
on published studies in pregnancies complicated with 
vasa previa. The second will involve in- depth interviews 
with current and former patients, their family members 
and healthcare providers who care for these patients. 
This will be followed by a two- round Delphi survey, 
which will aim to narrow down the long list of outcomes 
into those considered important by four groups of 
‘stakeholders’: (1) patients, family members and patient 
advocates/representatives, (2) healthcare providers, (3) 
researchers, epidemiologists and methodologists and (4) 
other stakeholders directly or indirectly involved in the 
management of these pregnancies such as administrators, 
guideline developers and policymakers. The fourth step will 
involve a face- to- face consensus meeting using a nominal 
group approach to establish a finalised core outcome set. 
The final step will involve measuring and defining the 
identified outcomes using a combination of systematic 
reviews and Delphi surveys.
Ethics and dissemination This study as well as consent 
forms for stakeholder participation have received approval 
from the Mount Sinai Hospital Research Ethics Board 
(REB number 18-0173- E) on 05 September 2018 and 
the Human Research Ethics Committee at The University 
of Technology Sydney, Australia on 30 July 2019 (UTS 
HREC reference number ETH19-3718). All progress will 
be documented on the international prospective register 
of systematic reviews and Core Outcome Measures in 
Effectiveness Trials databases.
Registration details http://www. comet- initiative. org/ 
studies/ details/ 1117.
INTRODUCTION
In approximately 7% of all singleton preg-
nancies, the umbilical cord inserts close to 
the edge of the placenta (marginal inser-
tion), and in 1% of cases, a more extreme 
variation is encountered, wherein the umbil-
ical cord inserts at the apex of the membra-
nous sac (velamentous cord insertion).1 In 
both these instances, fetal blood vessels could 
run unprotected outside the umbilical cord, 
in the membranes surrounding the baby; and 
when these membranous vessels cross the 
internal opening of the cervix, preceding the 
presenting fetal part, the condition is referred 
to as vasa previa.1 2 Spontaneous or artificial 
rupture of the membranes around the time 
of childbirth could result in a rupture of 
these vessels, putting the baby at risk of severe 
blood loss, hypotension, anaemia and death 
by exsanguination. Vasa previa is believed to 
affect one in 1667–2174 pregnancies (0.46–
0.60 per 1000 pregnancies).3 4 If vasa previa 
Strengths and limitations of this study
 ► This core outcome set, which is being developed 
by a multinational group of investigators that com-
prise the Outcome Reporting in Obstetric Studies 
project (https://www.obgyn.utoronto.ca/oros-proj-
ect), is supported by the International Vasa Previa 
Foundation and will draw input from numerous in-
ternational organisations to ensure global represen-
tation of all stakeholders.
 ► Core outcome set for studies on pregnant women 
with vasa previa will draw from outcomes reported 
in all published studies and trial registrations and 
will not exclude outcomes from studies that are at 
increased risk- of- bias, in order to obtain the most 
comprehensive initial list of outcomes.
 ► Increased emphasis is being placed on the quali-
tative steps of core outcome set development, in 
order to ensure that patient- reported outcomes and 
outcomes related to quality of life, resource use and 
functioning are considered alongside routinely re-
ported clinical outcomes.
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is not diagnosed antenatally, and prior to the onset of 
labour and vaginal delivery, approximately 40%–60% 
of newborns do not survive.5 6 Early diagnosis and the 
introduction of clear management plans are imperative 
for improving outcomes. However, there is no consensus 
on the optimal approach to antenatal diagnosis as well 
as various aspects of antenatal and peripartum manage-
ment.7 As a result, women who have been diagnosed with 
vasa previa have described feeling ‘like a ticking time 
bomb’ and expressed the reality of ‘coping with inconsis-
tent information’.8 Preferences of pregnant women with 
the condition and outcomes that they consider important 
have not yet been elucidated. Finally, the cost implications 
to healthcare systems from inpatient versus outpatient 
management and the use of various diagnostic modalities 
and management protocols have not been determined.
While these issues can be adequately addressed through 
well- conducted prospective studies, there is uncertainty 
with regards to the outcomes that should be measured in 
these studies and are considered important by pregnant 
women and other stakeholder groups including health-
care providers, researchers and policymakers. Deter-
mining this core set of outcomes that should comprise 
the bare minimum for inclusion in all further studies is 
therefore vital. A core outcome set is a set of outcomes 
that are considered important by those suffering from 
the condition, their family members and those involved 
in their care.9
The goal of this study is to gather patients’ and other 
stakeholders’ input regarding the outcomes important to 
them, and use this to create a core outcome set for studies 
on vasa previa which provide researchers with a list of 
outcomes that must be reported in all future studies, 
in order to improve its translational value and clin-
ical relevance. This project will reduce bias in outcome 
reporting, enable meta- analysis of published data to 
inform decision- making and provide an empiric basis for 
inclusion of stated outcomes based on input from rele-
vant stakeholders.
METHODS AND ANALYSIS
The protocol for this core outcome set for studies on 
vasa previa (COVasP) is registered on the Core Outcome 
Measures in Effectiveness Trials (COMET) website. It is 
guided by the COMET handbook9 and complies with the 
Core Outcome Set—Standardized Protocol Items state-
ment.10 As with other core outcome sets being developed 
as part of the University of Toronto’s Outcome Reporting 
in Obstetric Studies (OROS) project (https://www. obgyn. 
utoronto. ca/ oros- project), COVasP will be developed in 
five distinct steps, involving qualitative and quantitative 
research methods, as outlined in figure 1.11 12
Step 1: Systematic review
A systematic literature review will be undertaken to explore 
all reported outcomes in published studies involving 
pregnant women with vasa previa and will generate a 
preliminary list of outcomes that are deemed important 
and hence reported by researchers. The protocol for 
this systematic review, based on the Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses guide-
lines, is available on the international prospective register 
of systematic reviews—PROSPERO (CRD42018087837).
Study selection
Five bibliographic databases—Medline, Embase, 
Cochrane, PubMed (non- Medline and in- process) 
and  Clinicaltrials. gov will be searched from the incep-
tion. All interventions and exposures will be included. 
Randomised or non- randomised studies, prospective 
and retrospective cohort studies, case–control studies, 
case series, case reports, qualitative research as well as 
economic evaluation studies and decision analyses will 
be included in the search. We will exclude letters to the 
editor, commentaries, editorials, conference abstracts 
that do not describe clinical outcomes and reviews that 
do not report on outcomes or contain original research.
Data extraction
Extracted information will include details on study char-
acteristics such as publication year, number of partici-
pants, study type, number of included pregnancies, as 
well as individual and composite outcomes and their 
definitions, components and measurement instruments 
when available.
Quality assessment
As the purpose of this review is to identify reported 
outcomes and not to determine the effectiveness of 
management strategies, no assessment of the study’s 
methodological quality will be performed. Similarly, as 
the aim of this systematic review is to identify all reported 
outcomes in order to generate a long list of outcomes to 
inform the development of the core outcome set, and 
there is no validated tool to assess the quality of outcome 
reporting, it was decided a priori that the quality of 
outcome reporting of included studies would not be 
assessed.
Analysis and presentation of results
The proportion of studies reporting each outcome and 
the components will be documented. No subgroup or 
sensitivity analysis is proposed.
Step 2: Stakeholder consultation
In addition to identifying outcomes reported by 
researchers, we aim to understand what maternal and 
perinatal outcomes are considered important by women 
with a diagnosis of vasa previa, their family members, 
healthcare providers and researchers. Qualitative meth-
odology provides a scope for all relevant stakeholders to 
discuss their views on important outcomes and contrib-
utes to the robustness of core outcome set development 
by identifying the new outcomes that were not reported 
in the literature, exploring why the outcomes are consid-
ered important and understanding the scope and priority 
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of the outcomes.13 Our systematic literature review found 
only three qualitative studies on vasa previa; that were 
conducted with the women,8 midwives14 15 and obstetri-
cians.7 However, these studies were focused on eliciting 
experiences of patients and midwives, identifying barriers 
and challenges to care and determining variations in 
opinions and clinical practice. None specifically focused 
on identifying the outcomes that could inform the devel-
opment of COVasP. Hence, we will conduct a descrip-
tive–interpretive qualitative research study16 with the 
relevant stakeholders in high- income countries.
Inclusion criteria
We will include women who have had a diagnosis of vasa 
previa (current or previous) and their partners, health-
care providers who have cared for women with a diag-
nosis of vasa previa and healthcare professionals who 
have been involved in conducting research or develop-
ment of a policy/guideline in relation to vasa previa that 
are above the age of 18 and able to give informed consent 
and participate in an interview in English language. 
Women and their partners will be excluded if they (or 
their partners) had been diagnosed with vasa previa that 
was not confirmed at a later stage during pregnancy or 
birth.
Sampling
Women and their partners will be recruited through an 
established partnership with the International Vasa Previa 
Foundation (IVPF) (http:// vasaprevia. com). The IVPF 
is an all- volunteer charity created to promote awareness 
and provide support and advocacy to the general public 
and professionals regarding vasa previa. In 2018, the 
IVPF sent out an ‘Expression of Interest’ email to their 
members which was also shared on social media in rele-
vant peer- support groups as a means of recruitment. To 
ensure that the views of women with different experiences 
and backgrounds are represented, specific criteria (age, 
type of conception, time of diagnosis and country where 
care was received) will be selected to provide maximum 
variation sampling as outlined in table 1.13 In addition 
to the categories outlined in the table, it is hoped that 
recruiting patients through the IVPF, known contacts and 
other channels will enable us to access representatives of 
the following groups (a) those currently pregnancy with 
a confirmed diagnosis of vasa previa, (b) those who have 
had pregnancies that resulted in live births and those 
Figure 1 Steps in the development of a core outcome set for studies on vasa previa.
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who resulted in fetal or neonatal death, (c) pregnancies 
with a complicated and relatively uncomplicated ante-
natal course, (d) those whose babies suffered serious 
consequences of prematurity and (e) those who required 
unplanned/emergency caesarean deliveries versus 
those whose caesarean deliveries occurred as scheduled. 
Healthcare providers and researchers will be recruited 
through email using a study flyer, via contact lists assem-
bled by the study investigators. As is the norm with quali-
tative research, the exact sample size will be determined 
once data collection and analysis are commenced.17 
Based on the interviews, we have conducted with patients 
and healthcare professionals in this area, wherein data 
saturation was attained after the conduct of 14–20 inter-
views, we anticipate that we will conduct approximately 20 
patient interviews and 10–12 interviews with clinicians/
researchers until data saturation is reached and no new 
outcomes are identified in two successive interviews.
Consent
Information regarding the aims of the study and the 
process of interview will be provided to interested indi-
viduals in writing by means of a participant informa-
tion sheet, highlighting that participation is voluntary. 
Individuals will be given an opportunity to contact the 
researchers to receive more information before they 
make an informed consent to participate in an inter-
view. Only individuals who provide written and/or verbal 
consent will be interviewed.
Data collection
All interviews will be conducted online or over the phone. 
On commencement of the interview, the interviewer will 
confirm that the participant has read the participant 
information sheet and consent form and obtain verbal 
consent. The interviewer will then request certain demo-
graphic details, which the participants may or may not 
choose to answer. Demographic details will vary slightly 
depending on stakeholder group but include: age, occu-
pation, education, ethnicity and descriptions of their 
experiences with vasa previa or number of years working 
with this population, as appropriate. After a brief intro-
duction, and providing a description of the project and 
explanation of what constitutes health outcomes, the 
interview will commence. The interviews are designed to 
be semi structured and conversational using a topic guide 
(Online supplementary file 1). The goal is to ensure that 
the participant feels comfortable sharing their views and 
experience while ultimately eliciting health outcomes 
important to the participants who can then further inform 
our core outcome set development. During the reflective 
and iterative process of data collection and analysis, the 
topic guide may be refined and/or expanded to include 
the issues raised by earlier participants. One experienced 
qualitative researcher will conduct all the interviews 
by telephone or online. The interviews will be audio- 
recorded and transcribed verbatim.
Data analysis
Thematic data analysis18 taking a descriptive interpretive 
approach19 will start after the first interview. The data will 
be imported into NVivo V.12 software, which will assist 
with data management and analysis. Transcripts will be 
read and coded by a qualitative researcher (NJ) who 
conducted the interviews. The codes, emerging categories 
and the related quotes will be discussed with the research 
team, that includes at least one physician that cares for 
pregnant women with vasa previa, to reach agreement. 
Information and outcomes obtained through this qualita-
tive data analysis will be used to develop a list of outcomes 
deemed important by the participants, which will inform 
the subsequent Delphi study.
Step 3: Delphi methodology
Steps 1 and 2 generate a long list of outcomes considered 
important by researchers, women and other stakeholders 
involved in their care. The Delphi process that follows, 
is designed to achieve convergence of opinion on these 
outcomes, in an iterative and sequential manner.20 For 
this step, we will identify four groups of participants: (1) 
women, family members and patient advocates or repre-
sentatives, (2) healthcare providers, (3) researchers, 
epidemiologists/methodologists and core outcome set 
developers and (4) other stakeholders directly or indi-
rectly involved in the care of pregnant women such as 
administrators, guideline developers and policymakers. 
These groups represent all stakeholders directly or 
indirectly involved in the care of pregnancies affected 
by vasa previa. The Delphi survey will be developed by 
grouping the long list of outcomes (obtained through 
steps 1 and 2) into five core outcome areas—mortality, 
Table 1 Sampling matrix for purposive sampling of women 
with a history of vasa previa
Criteria
Target number of 
participants
Method of conception
  In vitro fertilisation 3–5
  Spontaneous conception 10–12
Pregnancy affected by vasa previa
  <5 years ago 6–8
  >5 years ago 6–8
Time of diagnosis of vasa previa
  During pregnancy 10–12
  During labour and childbirth 3–5
Continent
  North America 6–8
  Europe 6–8
  Australasia 6–8
  Africa 1–3
  South and Central America 2–3
Target total 20
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morbidity (clinical/physiological), life- impact (func-
tioning), resource- use and adverse events—based on 
a published taxonomy.21 Lay- language summaries will 
appear alongside complex medical outcomes. The survey 
will be piloted with at least 10 people including one 
person from each stakeholder group. Since we will be 
using a familiar software, retaining all outcomes obtained 
through steps 1 and 2, and using prepiloted lay- language 
summaries for common obstetric and neonatal outcomes 
developed by the OROS project,11 12 22 the only purpose 
of piloting the survey is to ensure that representatives of 
all stakeholder groups have an opportunity to comment 
on content unique to COVasP. We believe that a sample 
of 10 people to be sufficient for this step. After piloting, 
the survey will be made available online (through links 
on social media) and widely distributed through identi-
fied listservers of relevant organisations, including but 
not restricted to the Cochrane Pregnancy and Childbirth 
Group (30 members), the Global Obstetric Network (237 
members), Core Outcomes in Women’s and Newborn 
Health (CrOWN) initiative (77 members), corre-
sponding authors of publications on vasa previa included 
in a recent systematic review,23 IVPF, United Kingdom 
Obstetric Surveillance System (https://www. npeu. ox. 
ac. uk/ ukoss), UK Vasa Praevia Raising Awareness Trust 
(http:// vasapraevia. co. uk), Australasian Maternity 
Outcomes Surveillance System (https://www. amoss. 
com. au), Perinatal Society of Australia and New Zealand 
(https://www. psanz. com. au) and Vasa Praevia Support 
and Awareness Ireland (https://www. facebook. com/ 
vasa prae vias uppo rtan dawa rene ssIr eland). We will aim 
to recruit at least 25 individuals from each stakeholder 
group to ensure an appropriate degree of representation. 
An online approach using DelphiManager software will 
be employed, to ensure privacy, feasibility, cost effective-
ness and reliability, while facilitating global representa-
tion.9 On signing an online consent form and completing 
a brief demographic questionnaire, participants will be 
required to score each outcome on a 9- point Likert scale 
based on its perceived degree of importance. Scores of 
1–3 will be considered as ‘not essential’; 4–6, ‘important 
but not critical’ and 7–9, ‘critically important for inclu-
sion’.9 Participants will also be presented with a text box 
for them to enter any outcomes they deem important, 
which might not have been included in the list provided.
Analysis
For each outcome, scores will be plotted as histograms, 
stratified by the each participant’s self- reported group, 
as follows: (a) patients and patient advocates, (b) clini-
cians and (c) researchers. All new outcomes emerging 
from round 1, if deemed by COVasP investigators as 
distinct from those presented, will be included into the 
second round. On completion of first- round analysis, 
an invitation will be sent out to all members requesting 
participation in the second round. Each member scoring 
outcomes in the second round will have access to the 
histograms presenting first- round scores stratified by the 
participant group, to enable participants to decide on 
whether they would like to retain their original score, 
or modify it. Email reminders will be sent out to ensure 
that at least 85% of respondents complete both surveys, 
to prevent attrition bias. Each participant will be asked 
whether they would like to and be able to attend a face- 
to- face consensus meeting, details of which will be deter-
mined, by this juncture.
Missing data and attrition
Participants will be given clear outlined expectations of 
timelines and a 6- week window to complete each round 
of the survey. Should the response rate not achieve 80%, 
a level deemed acceptable by published recommenda-
tions,9 additional interventions will be implemented, 
guided by measures adopted by other core outcome set 
developers. Telephone calls, emails, personal reminders 
and extension of the survey deadlines may be used to 
improve the response rate. Any feedback after the first 
round regarding obstacles when completing the survey in 
its entirety will be noted and addressed before the second 
round.
Step 4: Consensus meeting
All outcomes that are deemed ‘critically important for 
inclusion’ (scores 7–9 on the second round of the Delphi 
survey) by 70% of all stakeholders will be included in the 
final core outcome set. This includes intermediary and 
surrogate outcomes. In addition, in order to ensure that 
the patient perspective is reflected, we will also retain and 
include in the final core outcome set, outcomes that are 
scored 7–9 by 70% of patients alone. Outcomes assigned 
scores 1–3 by >70% of all participants will be discarded. 
Outcomes assigned scores of 4–6 (important but not crit-
ical) by >70% of stakeholders will be further discussed at 
a face- to- face consensus meeting, which will use a struc-
tured variation of a small- group discussion called the 
nominal group technique.24 At the consensus meeting, 
participants will be first asked to independently decide 
whether each of these outcomes in question should be 
included in the core outcome set or not. This will be 
followed by small- group discussions, wherein members 
express their understanding of the logic and the relative 
importance of each of these ‘important but not critical’ 
outcomes and debate whether they should be included 
in the final core outcome set or not. The final list of 
outcomes deemed as critical to include in the final core 
outcome set, presented by each small group, will be 
reflective of the group’s overall preferences, and through 
mutual consensus will constitute the final core outcome 
set. The advantages of using nominal group technique is 
that the process prevents the domination of the discus-
sion by a single person, encourages all group members to 
participate and results in a set of recommendations that 
represent the group’s preferences.
This consensus meeting will occur over a half day and will 
be conducted in keeping with the specifications laid out 
by the Evaluation Research Team at the Centre for Disease 
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Control,24 and the entire process will be audio- recorded. 
Groups developing core outcome sets of obstetric condi-
tions have included between 14 and 29 participants in 
this step. Without prespecifying a number, we will aim to 
ensure equal representation of each stakeholder group 
and schedule this face- to- face meeting to coincide with 
an international obstetrics conference, in order to ensure 
global participation of representatives of various stake-
holder groups. However, we acknowledge that this might 
be difficult to organise, and therefore, in the interest of 
feasibility, might have to settle for organising this at the 
time of a local meeting, with most stakeholder represen-
tatives from within Canada. Since international represen-
tation will already have been sought through the Delphi 
survey, and on account of the cautious approach to elim-
inating outcomes described above, we do not believe this 
will compromise study integrity.
The OROS project, under whose initiative, COVasP is 
being developed, endeavours to achieve a balance between 
standardisation and comprehensiveness of outcome 
reporting. While the development of a core outcome set 
will address the former, the latter is important to ensure 
inclusion of maternal and fetal outcomes representing all 
core outcome areas,21 which include mortality/survival, 
clinical/physiological, life- impact/functioning, resource 
use and adverse events. There will, therefore, be no limit 
on the final number of outcomes constituting COVasP. 
As described in protocols for other core outcome sets 
being developed by the OROS group, all outcomes iden-
tified through the above process, will be presented in 
tabular form, separating maternal from fetal/neonatal 
outcomes, each stratified by the five main core outcome 
areas, and an online supplementary table highlighting 
all outcomes, their Delphi scores and the stages at which 
they were excluded will also be presented, for greater 
transparency.12
Step 5: Mmeasuring/defining core outcomes
On selection of a final list of core outcomes, we will 
employ the COnsensus- based Standards for the selection 
of health Measurement INstruments to assess measure-
ment tools/definitions for included outcomes based on 
four criteria: validity, responsiveness, reliability and inter-
pretability.25 We will begin the process by listing measure-
ment instruments and/or definitions for outcomes where 
universal agreement exists. For outcomes where there 
is a lack of agreement on measurement instruments or 
definitions, we will conduct systematic reviews to deter-
mine all currently used instruments and definitions. 
This will be followed by Delphi surveys involving relevant 
stakeholder groups as required, to determine the most 
appropriate definition or measurement instrument for 
each identified core outcome where systematic reviews 
are inconclusive.26 Details of this process will depend on 
the final list of outcomes and are beyond the scope of 
this protocol.
Patient and public involvement
Although the steps of developing a core outcome set are 
standardised, we will involve patients and other stake-
holders to participate in steps 2–4, through interviews, the 
Delphi survey and a consensus meeting. The purpose of 
their involvement is to determine what outcomes related 
to vasa previa are most important to them. The design of 
the study encourages stakeholders to consider outcomes 
related to domains such as functioning, resource use, 
satisfaction, compliance, healthcare delivery and mental 
health concerns in addition to the clinical and physio-
logical outcomes most commonly reported in research 
studies. We have taken steps to ensure that these outcomes 
considered important by patients are represented in the 
final core outcome set. We aim to involve patients in 
ensuring that COVasP is disseminated widely through 
the IVPF webpage and also through social media, in addi-
tion to ensuring knowledge translation to clinicians and 
researchers. The findings of each step of COVasP devel-
opment will be published on the OROS website (https://
www. obgyn. utoronto. ca/ oros- project), enabling ongoing 
feedback from patients and the public.
DISCUSSION
COVasP aims to provide researchers and clinicians with 
a systematically derived list of outcomes, incorporating 
preferences of patients and other relevant stakeholders, 
which will form the minimum standard required to be 
collected, measured and recorded as a baseline in all 
clinical studies on vasa previa. Input from various stake-
holder groups will enhance the quality and relevance 
of future studies on vasa previa and go a long way in 
improving outcomes that are considered most important 
by those that are affected by this rare but serious obstetric 
condition.
ETHICS AND DISSEMINATION
This study as well as consent forms for stakeholder partic-
ipation have received approval from the Mount Sinai 
Hospital Research Ethics Board (REB number 18-0173- E) 
on 05 September 2018 and the Human Research Ethics 
Committee at The University of Technology Sydney, 
Australia on 30 July 2019 (UTS HREC reference number 
ETH19-3718). The findings of the systematic review, 
patient interviews and final COS will be published in 
open- access journals and presented at national and 
international obstetrics and maternal–fetal medicine 
conferences. All progress will be documented on the 
PROSPERO, COMET and CROWN databases and made 
freely available through the IVPF webpage. Corresponding 
authors of studies included in the systematic review and 
participants in the qualitative interviews, Delphi surveys 
and consensus group meetings will be provided with a 
copy of all publications related to COVasP, to encourage 
its dissemination and use in future studies on the topic.
7D’Souza R, et al. BMJ Open 2020;10:e034018. doi:10.1136/bmjopen-2019-034018
Open access
Author affiliations
1Division of Maternal- Fetal Medicine, Department of Obstetrics & Gynaecology, 
Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
2Lunenfeld- Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, 
Canada
3University of Utah School of Medicine, Salt Lake City, Utah, USA
4Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
5International Vasa Previa Foundation, Chester, Illinois, United States
6The National Perinatal Epidemiology and Statistics Unit, Centre for Big Data 
Research in Health, University of New South Wales, Sydney, New South Wales, 
Australia
7Sydney Institute for Women, Children and their Families, Royal Prince Alfred 
Hospital, Camperdown, New South Wales, Australia
8Faculty of Health, University of Technology Sydney, Sydney, New South Wales, 
Australia
Correction notice This article has been corrected since it was published. The 
affiliations for author Nasrin Javid have been updated.
Twitter Rohan D’Souza @singingOB
Contributors RD conceived the idea, has experience with mixed- methods study 
design and development of core outcome sets and is the principal investigator and 
the founder of the Outcome Reporting in Obstetric Studies project. NJ designed the 
qualitative research components of the study. LV, CH and MS helped with drafting 
various aspects of the manuscript. JK is a maternal–fetal medicine physician with 
clinical expertise in the management of vasa previa. MK, ND and NJ represent 
the International Vasa Previa Foundation. NJ, RD, JK, MK and ND secured funding 
for the study. All authors contributed to and approved the final version of the 
manuscript prior to submission.
Funding This study is funded by the David Henderson- Smart 2019 Scholarship 
awarded to Nasrin Javid by the Perinatal Society of Australia and New Zealand, and 
the International Vasa Previa Foundation (IVPF).
Competing interests MK and ND are directors and NJ is a member of the 
International Vasa Previa Foundation that has provided part funding for this project. 
RD has received speaking honoraria from Ferring, Canada for presentations 
unrelated to this project.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting or dissemination plans of this research. Refer to the 
Methods section for further details.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iD
Rohan D’Souza http:// orcid. org/ 0000- 0002- 4049- 2017
REFERENCES
 1 Baergen R. Manual of pathology of the human placenta. Second ed. 
Boston, MA: Springer, 2011.
 2 Benirschke K, Burton G, Baergen R. Pathology of the human 
placenta. Sixth ed. Berlin Heidelberg: Springer, 2012.
 3 Pavalagantharajah S, Villani LA, D’Souza R. Vasa previa and 
associated risk factors: a systematic review and meta- analysis. Am J 
Obstet Gynecol MFM 2020:100117.
 4 Ruiter L, Kok N, Limpens J, et al. Incidence of and risk indicators for 
vasa praevia: a systematic review. BJOG 2016;123:1278–87.
 5 Sullivan EA, Javid N, Duncombe G, et al. Vasa previa diagnosis, 
clinical practice, and outcomes in Australia. Obstet Gynecol 
2017;130:591–8.
 6 Oyelese Y, Catanzarite V, Prefumo F, et al. Vasa previa: the impact of 
prenatal diagnosis on outcomes. Obstet Gynecol 2004;103:937–42.
 7 Javid N, Hyett JA, Walker SP, et al. A survey of opinion and practice 
regarding prenatal diagnosis of vasa previa among obstetricians from 
Australia and New Zealand. Int J Gynaecol Obstet 2019;144:252–9.
 8 Javid N, Sullivan EA, Halliday LE, et al. "Wrapping myself in cotton 
wool": Australian women's experience of being diagnosed with vasa 
praevia. BMC Pregnancy Childbirth 2014;14:318.
 9 Williamson PR, Altman DG, Bagley H, et al. The comet Handbook: 
version 1.0. Trials 2017;18:280.
 10 Kirkham JJ, Gorst S, Altman DG, et al. Core outcome Set- 
STAndardised protocol items: the COS- STAP statement. Trials 
2019;20:116.
 11 Dadouch R, Faheim M, Juando- Prats C, et al. Development of a core 
outcome set for studies on obesity in pregnant patients (COSSOPP): 
a study protocol. Trials 2018;19:655.
 12 D'Souza R, Hall C, Sermer M, et al. Development of a core outcome 
set for studies on cardiac disease in pregnancy (COSCarP): a study 
protocol. Trials 2020;21:300.
 13 Keeley T, Williamson P, Callery P, et al. The use of qualitative 
methods to inform Delphi surveys in core outcome set development. 
Trials 2016;17:230.
 14 Javid N, Hyett JA, Homer CS. Providing quality care for women with 
vasa praevia: challenges and barriers faced by Australian midwives. 
Midwifery 2019;68:91–8.
 15 Javid N, Hyett JA, Homer CSE. The experience of vasa praevia 
for Australian midwives: a qualitative study. Women Birth 
2019;32:185–92.
 16 Elliott R, Timulak L. Descriptive and interpretive approaches to 
qualitative research. In: Miles J, Paul G, eds. A Handbook of research 
methods for clinical and health psychology. Oxford University Press, 
2005: 147–59.
 17 Patton MQ. Qualitative evaluation and research methods. 2nd ed. 
Thousand Oaks, CA, US: Sage Publications, 1990.
 18 Creswell J. Qualitative inquiry & research design: choosing among 
five approaches. Thousand Oaks, CA, USA: Sage Publications, 2007.
 19 Thorne S, Kirkham SR, MacDonald- Emes J. Interpretive description: 
a noncategorical qualitative alternative for developing nursing 
knowledge. Res Nurs Health 1997;20:169–77.
 20 Sinha IP, Smyth RL, Williamson PR. Using the Delphi technique 
to determine which outcomes to measure in clinical trials: 
recommendations for the future based on a systematic review of 
existing studies. PLoS Med 2011;8:e1000393.
 21 Dodd S, Clarke M, Becker L, et al. A taxonomy has been developed 
for outcomes in medical research to help improve knowledge 
discovery. J Clin Epidemiol 2018;96:84–92.
 22 King A, D’Souza R, Teshler L NS, et al. The development of a 
core outcome set for studies on pregnancy- associated venous 
thromboembolism (COSPVenTE): a study protocol. BMJ Open 
2020. [This paper has been accepted by BMJ Open. Please add 
appropriate reference details].
 23 Villani LA, Pavalagantharajah S, D’Souza R. Variations in reported 
outcomes in studies on vasa previa: a systematic review. Am J 
Obstet Gynecol MFM 2020:100116.
 24 CDC. Gaining consensus among stakeholders through the nominal 
group technique. evaluation Briefs (7): United States department 
of health and human services. centers for disease control and 
prevention, 2018. Available: https://www. cdc. gov/ healthyyouth/ 
evaluation/ pdf/ brief7. pdf
 25 Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist 
for assessing the methodological quality of studies on measurement 
properties of health status measurement instruments: an 
international Delphi study. Qual Life Res 2010;19:539–49.
 26 Prinsen CAC, Vohra S, Rose MR, et al. How to select outcome 
measurement instruments for outcomes included in a "Core 
Outcome Set" - a practical guideline. Trials 2016;17:449.
